

July 15, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

To,
Glenmark Life Sciences Limited
Plot No 170-172
Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213

Dear Sir/Madam,

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 in connection with the disposal of equity shares of Glenmark Life Sciences Limited (“GLS”)

Dear Sir / Ma'am,

In terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as amended, intimation be and is hereby given that the Company has disposed 96,09,571 equity shares representing 7.84% of the issued and paid-up equity share capital of GLS through offer for sale on separate designated windows of BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) in accordance with the procedure prescribed by Securities and Exchange Board of India, BSE and NSE.

Copy of disclosure required under Regulation 29(2) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, is enclosed herewith for your reference.

For Glenmark Pharmaceuticals Limited


Harish Kuber
Company Secretary and Compliance Officer



Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC).	Glenmark Life Sciences Limited		
Name of the seller and Persons Acting in Concert (PAC) with the seller	Glenmark Pharmaceuticals Limited		
Whether the seller belongs to Promoter/Promoter group	Yes***		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition/disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the disposal under consideration, holding of:			
a) Shares carrying voting rights	96,09,571	7.84%	7.84%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	96,09,571	7.84%	7.84%
Details of acquisition/sale:			
a) Shares carrying voting rights acquired/sold	96,09,571	7.84%	7.84%
b) VRs acquired/sold otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d) Shares encumbered/invoked/released by the acquirer	-	-	-
e) Total (a+b+c+d)	96,09,571	7.84%	7.84%
After the acquisition/sale, holding of:			
a) Shares carrying voting rights	0	0	0



b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after disposal	-	-	-
e) Total (a+b+c+d)	0	0	0
Mode of acquisition/sale (e.g., open market/off-market/public issue/rights issue/preferential allotment/inter-se transfer etc.)	Offer for sale (OFS)		
Date of acquisition/sale of shares/VR or date of receipt of intimation of allotment of shares, whichever is applicable	July 11, 2024 and July 12, 2024		
Equity share capital/total voting capital of the TC before the said acquisition/sale	12,25,27,172 equity shares of face value INR 2 each		
Equity share capital/total voting capital of the TC after the said acquisition/sale	12,25,27,172 equity shares of face value INR 2 each		
Total diluted share/voting capital of the TC after the said disposal	12,25,27,172 equity shares of face value INR 2 each		

(*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of TC.

(***) The Company has submitted an application dated March 22, 2024 for the reclassification of Glenmark Pharmaceuticals Limited and Mr. Glenn Mario Saldanha from 'promoter and promoter group' to 'public' shareholders to the BSE and NSE. The application is currently pending.

Signature of Authorised Signatory




V.S. Mani
Executive Director and Global Chief Financial Officer

Place: Mumbai
Date: July 15, 2024